NCT00697775 - Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

March 31, 1998

Primary Completion Date

May 31, 1999

Conditions

Hepatitis B

Interventions

BIOLOGICAL

HBV-MPL vaccine Formulation A

Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection

BIOLOGICAL

HBV-MPL vaccine Formulation B

2-dose intramuscular injection

BIOLOGICAL

Engerix™-B

Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection

Trial Locations (1)

GSK Clinical Trials Call Center, Mainz